We have identified a variant in ADCY3 (encoding adenylate cyclase 3) associated with markedly increased risk of obesity and type 2 diabetes in the Greenlandic population. The variant disrupts a splice acceptor site, and carriers have decreased ADCY3 RNA expression. Additionally, we observe an enrichment of rare ADCY3 loss-of-function variants among individuals with type 2 diabetes in trans-ancestry cohorts. These findings provide new information on disease etiology relevant for future treatment strategies.
We have identified a variant in ADCY3 (encoding adenylate cyclase 3) associated with markedly increased risk of obesity and type 2 diabetes in the Greenlandic population. The variant disrupts a splice acceptor site, and carriers have decreased ADCY3 RNA expression. Additionally, we observe an enrichment of rare ADCY3 loss-of-function variants among individuals with type 2 diabetes in trans-ancestry cohorts. These findings provide new information on disease etiology relevant for future treatment strategies.
Identification of homozygous loss-of-function mutations in humans may readily provide information about the biological impact of specific genes and point to novel drug targets. We previously identified a loss-of-function variant in TBC1D4 segregating at high frequency in the Greenlandic population and displaying a large impact on risk of type 2 diabetes 1 , confirming the advantage of studying the Greenlandic population due to its extreme demographic history 2 . Motivated by this, we screened for new loss-offunction variants in exome sequencing data from the 27 individuals in nine trios which were used to identify the causal TBC1D4 lossof-function variant 1 . We identified 46 such variants (Supplementary Table 1 ) and intersected the location of these variants with loci known to associate with obesity or body mass index (BMI) ( Supplementary Fig. 1 ). One of the variants, which was present in one copy in one of the parents in one trio, was situated in a locus where a common noncoding variant has been shown to be associated with BMI in adults and children in genome-wide association studies (GWAS) 3, 4 . The variant (hg19: chromosome 2: 25050478[C> T], c.2433-1G> A) is predicted to abolish a splice acceptor site in exon 14 (NM_004036.4) of ADCY3 (Fig. 1a ). For this reason, we investigated the specific variant further by genotyping this site in two Greenlandic cohorts. This analysis showed that the variant has an overall minor allele frequency (MAF) of 2.3% in the Greenlandic study population (N = 4,038, N heterozygous = 172, N homozygous = 7) and a frequency of 3.1% in the Inuit-ancestry part of the population. Notably, the seven homozygous carriers had BMI that was 7.3 kg/m 2 higher (P = 0.00094) than the BMI of the remaining study population (Table 1 ). We also observed that three of the seven homozygous carriers had type 2 diabetes (P = 7.8 × 10 −5 ; Table 1 ), while one had impaired fasting glucose and one had impaired glucose tolerance. Notably, the association with type 2 diabetes remained significant after adjustment for BMI (P = 6.5 × 10 −4 ), suggesting that it is not simply mediated by increased BMI. The effects on BMI and type 2 diabetes were also observed, although with smaller sizes, when data were analyzed according to an additive genetic model (Table 1) . However, when we compared the recessive and additive models with the full genotype model, we rejected the additive model (BMI, P = 0.002; type 2 diabetes, P = 0.004) but not the recessive model (BMI, P = 0.17; type 2 diabetes, P = 0.095). This suggests that the recessive model is appropriate for explaining the effect of the ADCY3 c.2433-1G> A variant.
To further characterize homozygous carriers of ADCY3 c.2433-1G> A in the Greenlandic cohorts, we analyzed a number of additional traits related to BMI and type 2 diabetes. The homozygous carriers had a body fat percentage that was 8.1 percentage points higher (P = 0.0024) and a waist circumference that was 17 cm larger (P = 0.0017). In addition, the homozygous carriers had nominally higher levels of fasting and 2-h plasma glucose in an oral glucose tolerance test (P = 0.022 and P = 0.035, respectively; Table 1 ). Finally, we also observed nominally significant effects of the variant on dyslipidemia and insulin resistance (Supplementary Table 2 ).
The c.2433-1G> A ADCY3 variant was not observed in sequencing data of up to 138,000 individuals from non-Greenlandic populations collected by the Genome Aggregation Database Consortium 5 (gnomAD). To generalize our findings to other populations, we therefore investigated the effect of loss-of-function variants in ADCY3 more generally by analyzing 18,176 samples with exome sequence data generated by the GoT2D, T2DGenes, SIGMA and LuCAMP consortia [6] [7] [8] , which are available at the Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal (AMP-T2D). No homozygous carriers of ADCY3 loss-of-function variants were observed in this dataset, but the analysis included seven predicted ADCY3 loss-of-function variants ( Fig. 1a ) observed in the heterozygous form in eight individuals and we observed an enrichment of carriers among type 2 diabetes cases as compared with non-diabetic controls (7/8,845 in cases, 1/9,323 in controls, odds ratio (OR) = 8.6, P = 0.044; Supplementary Tables 3-5 ). To further substantiate these findings, exome sequence data from 9,928 Finnish individuals from the METSIM cohort 9 were screened for loss-of-function variants in ADCY3; however, none were identified (M. Laakso (Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital), personal communication). Furthermore, we did not find any loss-offunction ADCY3 variants in whole-genome sequence data for 3,124 individuals from two isolated Greek populations that were part of the HELIC study 10 . Finally, in up to 138,000 individuals in the gno-mAD data, 48 predicted loss-of-function variants were found. All variants had MAFs below 0.007%, and only a single homozygous carrier was found for the African-specific c.1072-1G> A loss-offunction variant in ADCY3. Because we cannot obtain phenotypic data for the gnomAD samples, we are unable to evaluate the impact of these variants on obesity and type 2 diabetes.
Loss-of-function variants in ADCY3 increase risk of obesity and type 2 diabetes
To investigate the functional impact of the ADCY3 c.2433-1G> A variant, we performed deep RNA sequencing in leukocytes from 17 Greenlandic individuals (7 GG carriers, 6 GA carriers and 4 AA carriers). The RNA sequencing data confirmed that ADCY3 was expressed in homozygous carriers of the wild-type allele (GG carriers) and that exon 14 (NM_004036.4) of ADCY3 was expressed and spliced in its canonical form ( Supplementary Fig. 2a ). Inclusion of exon 14 in the mature mRNA was further confirmed by RNA sequence data from the adipose tissue of a healthy Europeanancestry female donor 11 . Notably, we found that the overall RNA expression level of ADCY3 was severely decreased in homozygous carriers of the variant (AA), while heterozygous carriers (GA) showed an intermediate expression level (Fig. 1b ). The RNA sequencing data further confirmed that the predicted disruption of the exon 14 splice acceptor site by the c.2433-1G> A variant has an impact on molecular phenotype. Specifically, the data predict that two novel ADCY3 isoforms are expressed in variant carriers: one transcript where exon 14 is skipped and an alternative splice acceptor site at exon 15 is used and one transcript in which the intron between exon 13 and exon 14 is retained ( Supplementary Fig. 2b ). We quantified these alternative splicing events by comparing expression of the three predicted ADCY3 isoforms using isoform fraction (IF) ( Fig. 1c ) and the percentage spliced in (PSI) at the relevant splice sites ( Supplementary Fig. 2b ). Both analyses demonstrated that homozygous AA carriers had a severely affected splicing pattern and mainly used intron retention (median IF = 0.38, median PSI = 75%) or exon skipping (IF = 0.53, PSI = 24%), while wildtype GG carriers had the canonical splicing pattern (IF = 0.88, PSI = 87%). In all analyses, heterozygous carriers showed an intermediate level of alternative splicing ( Fig. 1c and Supplementary  Fig. 2b,c) . Notably, we predict the isoform with intron retention to be sensitive to nonsense-mediated decay owing to the introduction of a premature stop codon 12 (Fig. 1a ). This predicted degradation naturally would lead to further reduction of ADCY3 protein levels.
ADCY3 encodes an adenylate cyclase with a wide tissue distribution showing high levels in subcutaneous and visceral adipose tissue, intermediate levels in brain, and rather low levels in pancreas and skeletal muscle in Genotype-Tissue Expression (GTEx) project data. ADCY3 catalyzes the synthesis of cyclic AMP (cAMP) from ATP. cAMP is an essential second messenger in intracellular signaling downstream of key metabolic mediators such as glucagon-like peptide 1, ghrelin and α -melanocyte-stimulating hormone 13 , and cAMP signaling has been linked to control of adipose tissue development and function, as well as insulin secretion in beta cells 14 . In addition, mouse models have indicated that ADCY3 has an important role in the regulation of adiposity and glucose homeostasis. Hence, in mice, Adcy3 haploinsufficiency causes impaired insulin sensitivity and dyslipidaemia 15 , Adcy3 gain of function protects against dietinduced obesity 16 and Adcy3-knockout mice show increased fat mass, hyperphagia, depression-like phenotypes and leptin resistance 17, 18 . Possibly, leptin resistance occurs through disrupted cAMP signaling in primary cilia in hypothalamus, affecting the downstream signaling and morphology of neurons 17 . Interestingly, previously described syndromic forms of obesity, including Bardet-Biedl and Alström syndromes, have been found to be caused by altered function of primary cilia and are, in addition to obesity, characterized by diabetes 19 . Furthermore, common variation in ADCY5, a gene in the same family as ADCY3, is known to be associated with fasting plasma glucose levels and risk of type 2 diabetes 20 .
In humans, common variants in the ADCY3 locus have been associated with higher BMI 3, 4 and total as well as truncal fat mass 21 . Thus, the phenotype observed in Greenlandic individuals homozygous for the loss-of-function variant, characterized by truncal adiposity, insulin resistance, dyslipidemia and type 2 diabetes, is in accordance with and elaborates on the phenotype observed for GWAS-identified variants. Our findings for carriers of loss-of-function variants implicate ADCY3 as the causal transcript in the reported GWAS-identified locus, and coherent evidence from genetic and biological studies suggest that pharmacological modulation of this target may possibly be a valid future therapy for obesity and type 2 diabetes.
In conclusion, we identified an ADCY3 loss-of-function variant in a Greenlandic Inuit population that increases adiposity and risk of type 2 diabetes in homozygous carriers and, to a lesser extent, in heterozygous carriers. Concomitantly, we detected decreased ADCY3 RNA expression levels in homozygous carriers and, again to a lesser extent, in heterozygous carriers. Furthermore, we show that the variant disrupts a splice acceptor site, triggering exon skipping or intron retention, where the latter is predicted to confer nonsense-mediated decay. The association with type 2 diabetes was substantiated in heterozygous carriers of rare ADCY3 variants across ancestry groups, underlining the possible role of ADCY3 as a future target for the prevention and treatment of obesity and type 2 diabetes.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-017-0022-7. Results are shown for a recessive and an additive genetic model. β SD and SE SD are the effect size and standard error estimated using quantile-transformed values of the trait (except for the binary trait type 2 diabetes), and β is the effect size estimated using untransformed values. P values were obtained from the analyses of quantile-transformed traits (except for the binary trait type 2 diabetes). P values shown have not been corrected for multiple testing; nominally significant P values are highlighted in bold.
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Methods Study samples. The Greenlandic samples are from two different cohorts: B99 (N = 1,401) and Inuit Health in Transition (IHIT) (N = 3,115), which were collected in Greenland as a part of general population health surveys conducted in 1999-2001 and 2005-2010, respectively 22, 23 . Two hundred and ninety-five individuals overlapped between the two cohorts and were assigned to the B99 dataset. Clinical characteristics of the participants are shown in Supplementary Table 6 . Phenotypic data. Height and weight were measured while participants were wearing light indoor clothes. Waist circumference was measured midway between the rib cage and the iliac crest, and hip circumference was measured at its maximum. Weight was measured on a standard electronic clinical scale.
Fat percentage was calculated from bioimpedance measurements (Tanita, TBF-300MA) in IHIT participants. Intra-abdominal adipose tissue was assessed by ultrasonography, which is considered to be a valid and reproducible method as compared with computerized axial tomography (CT) scans and magnetic resonance imaging (MRI) 24 , using a 3.5-MHz transducer with the participant in supine position and at the end of a normal expiration. Tests for intra-and inter-observer variation were performed in IHIT, and results were in the range of 1.9-5.6% 25 . In IHIT, all participants underwent an oral glucose tolerance test (OGTT). In B99, participants above 24 years of age had fasting blood samples taken and participants above 35 years of age underwent an OGTT. At the baseline health examination, venous blood samples were drawn after an overnight fast of at least 8 h. After this, participants received a standard 75-g OGTT, with blood samples drawn 2 h after glucose intake. Only fasting venous plasma glucose was measured in participants with known diabetes. Fasting and 2-h plasma glucose values were analyzed with the Hitachi 912 system (Roche Diagnostics). Fasting and 2-h serum insulin levels were analyzed by an immunoassay method excluding des-31,32 split products and intact proinsulin (AutoDELFIA; Perkin Elmer). Indices of insulin sensitivity and insulin secretion were derived from plasma glucose and serum insulin measures from the OGTT. Hepatic insulin sensitivity was estimated by the homeostasis model assessment (HOMA-IR = fasting glucose × (fasting insulin/6.945)/22.5) 26 and by a peripheral insulin sensitivity index (ISI 0,120 ) calculated as ISI 0,120 = (((75,000 + (fasting glucose × 18 -2-h glucose × 18) × 0.19 × weight (kg))/120)/((fasting glucose × 18 + 2-h glucose × 18)/2))/log((fasting insulin/6.945 + 2-h insulin/6.945)/2) 27 , where serum insulin is expressed in pM and plasma glucose in mM. Analyses of quantitative glycemic traits were performed excluding individuals with previously diagnosed diabetes. Individuals taking lipid-lowering medication were removed in analysis of fasting serum lipids. Dichotomous glycaemia variables were constructed to test for association with type 2 diabetes classified according to the World Health Organization criteria 28 .
Identification and selection of loss-of-function variants to study.
To identify new loss-of-function variants in the Greenlandic population, we used the exome data from 27 Greenlandic individuals in nine trios presented previously 1 . In this dataset, we identified 46 loss-of-function variants, which were not present in dbSNP (version 138 and below) and that were not present in the NHLBI Exome Sequencing Project (ESP) (Supplementary Table 1 ). We then used the GWAS catalog (downloaded January 2013) to assign known associations to the loci with the lossof-function variants using associations with P values of less than 10 −7 . Finally, we selected the variants with known associations to obesity or BMI for further study. This selection procedure left us with one predicted loss-of-function variant, ADCY3 c.2433-1G> A ( Supplementary Fig. 1 ). This variant is located in ADCY3 and was present in a single parent in one of the nine trios in heterozygous form.
Genotype data. Subsequently, we genotyped ADCY3 c.2433-1G> A in the two Greenlandic cohorts, IHIT and B99, using the KASP Genotyping Assay (LGC Genomics). The genotyping call rate was 99.2%, and no mismatches were observed in 362 samples genotyped in duplicate. For the association testing, we used qualityfiltered Metabochip genotype data on which to base our genetic similarity matrix estimates. The genotyping and quality filtering of the Metabochip data have been described in detail earlier 29 . The filtered Metabochip dataset contains data from 2,791 individuals from IHIT and 1,336 individuals from B99, and we have ADCY3 c.2433-1G> A genotyping data for 4,038 of these individuals, 2,779 from IHIT and 1,259 from B99.
Association testing and replication. Greenlandic cohorts.
To test for association between the ADCY3 variant and the different phenotypes of interest, we used a linear mixed model, implemented in the software GEMMA 30 , to account for relatedness and admixture 1 . For each phenotype, GEMMA was applied to data from the subset of individuals across the two cohorts with information available about that specific phenotype. The genetic similarity matrix required as input to GEMMA was estimated from Metabochip genotype data 1 . For each phenotype, we performed two association tests: a test where we assumed a recessive effect model and a test where we assumed an additive effect model. All tests were performed with sex, age and cohort included as covariates. An additional analysis also included BMI as a covariate. Before all tests for association with quantitative traits, we quantile transformed the phenotype data to a normal distribution separately for each sex, which gave the results reported as β SD , SE SD and P. However, to get effect sizes in the units in which the traits were measured, we also performed the analyses without transforming the phenotype data, which resulted in the results reported as β. For the binary trait type 2 diabetes, we did not perform any transformation and the test results are reported as β and P.
To assess the appropriateness of the recessive effect model and the additive effect model for BMI and type 2 diabetes, we compared each of these effect models against a full genotype model, where each of the three genotypes have an independent effect. To do this, we used the same linear model framework as we did for the association tests. These additional tests were only performed in the IHIT cohort because there were no homozygous carriers in B99, which in practice means the tests cannot be performed if B99 is included.
Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal (AMP-T2D).
Data from AMP-T2D generated as part of the GoT2D, T2DGenes, SIGMA and LuCAMP consortia [6] [7] [8] were queried for association between a burden of lossof-function variants in ADCY3 and type 2 diabetes. The data contained 18,869 samples with exome sequence data, of which 18,176 samples were informative for type 2 diabetes. Samples originated from five ancestries (6, 356 European, 5, 722 Hispanic, 2,199 South Asian, 2,158 East Asian and 1,741 African American). Variants annotated as stop-gain or frameshift variants or variants in a splice adaptor/donor site were considered loss of function. Burden association analyses were performed with each individual coded as carrying a loss-of-function variant or not. We used logistic regression and adjusted for principal components 1-4 as well as age and sex by including these as covariates. We also analyzed all other genes with at least five loss-of-function variants with at least one mutation carrier for each variant. Only loss-of-function variants with MAF < 5% were used. This analysis showed that there is no general inflation in the test statistic ( Supplementary Fig. 3 ).
Greek isolated populations. As part of the HELIC study 10 , 1,642 samples from the Pomak villages in northern Greece and 1,482 samples from the Mylopotamos villages in Crete were sequenced at an average depth of 18.6× and 22.5× , respectively, using the HiSeqX platform. Adaptor-ligated libraries were amplified by six cycles of PCR and subjected to DNA sequencing according to the manufacturer's instructions. Genomic (G)VCFs were created for 200 equally sized chunks using GATK HaplotypeCaller v3.5, combined into batches of 150 samples using GATK CombineGVCFs and called using GATK GenotypeGVCFs. Variantlevel quality control was performed using GATK VQSR v.3.5.
Estimation of admixture proportions, ancestral allele frequencies and relatedness.
For the Greenlanders, all admixture proportions were obtained from ref. 1 . To estimate the ancestral Inuit allele frequencies for the ADCY3 variant, we performed maximum-likelihood estimation using the likelihood model from ADMIXTURE 31 with the admixture proportions fixed and including only genotype data from the variant of interest. To achieve the maximum-likelihood estimates, we applied an EM algorithm. We estimated relatedness using relateAdmix 32 based on the estimated admixture proportions. None of the seven homozygous carriers are closely related to each other (second-degree relatives or closer); however, one pair may be first cousins with an estimated kinship coefficient of 0.08.
RNA sequencing analysis.
RNA sequencing was performed on leukocytes from 17 Greenlandic individuals (7 GG carriers, 6 GA carriers and 4 AA carriers). Total RNA was extracted from 2.5 ml of peripheral blood with the PAXgene Blood miRNA kit (Qiagen) according to the manufacturer's protocol and subjected to on-column DNase I treatment with RNase-free DNase (Qiagen). RNA quality and purity were checked using an Agilent 2100 Bioanalyzer (Agilent RNA 6000 Nano Kit) and NanoDrop, respectively.
The RNA sequencing library was prepared following the instructions of the TruSeq RNA Sample Prep Kit v2 (Illumina). For mRNA isolation and fragmentation, 200 ng of total RNA was purified on oligo(dT) beads before fragmentation with Elute, Prime, Fragment Mix. First-strand cDNA was generated using First-Strand Mix and SuperScript II (Invitrogen) reverse transcription master mix (reaction conditions: 25 °C for 10 min; 42 °C for 50 min; 70 °C for 15 min). The second strand was synthesized by adding Second-Strand Master Mix (16 °C for 1 h). The fragmented cDNA was end-repaired and purified with AMPure XP Beads (Agencourt). A-Tailing Mix was added, and reactions were incubated at 37 °C for 30 min. For adaptor ligation, Adenylate 3′ Ends DNA, RNA Index Adaptor and Ligation Mix were mixed and reactions were incubated at 30 °C for 10 min. End-repaired DNA was purified with AMPure XP Beads (Agencourt). Several rounds of PCR amplification with PCR Primer Cocktail and PCR Master Mix were performed to enrich the cDNA fragments. The PCR products were purified with AMPure XP Beads (Agencourt). The average molecule length was measured using the Agilent 2100 Bioanalyzer instrument (Agilent DNA 1000 Reagents) and by real-time qPCR (TaqMan Probe). The qualified libraries were amplified on a cBot to generate the cluster on the flow cell (TruSeq PE Cluster Kit V3-cBot-HS, Illumina). The amplified flow cell was sequenced using paired-end reads on the HiSeq 4000 system (TruSeq SBS Kit-HS V3, Illumina).
The obtained RNA-seq libraries, as well as one RNA-seq library from adipose tissue of a healthy European-ancestry female 11 , were processed by Trimmomatic v 0.32 33 , trimming the reads using HEADCROP:11 LEADING:22 SLIDINGWINDOW:4:22 MINLEN:25. The quality of all libraries was checked with FastQC, before and after trimming. Trimmed reads were mapped unstranded to the human reference genome (hg19) using Hisat2 v2.0.1-beta 34 with splice-site information from GENCODE v19 35 and set to annotate properly paired reads as those with a minimum insert size from 0 to 1,000 nt. Sashimi plots 36 were generated from the IGV genome browser 37 . PSI was calculated as r exon:intron /(r exon:intron + r exon:exon ), where r is the number of reads indicating the different splice patterns. r exon:intron was obtained by extracting relevant GENCODE v19 35 exon:intron boundaries ± 3 nt. Reads mapping to these regions were quantified using featureCounts from the R package Rsubread 38 specifying countChimericFragments = FALSE and minOverlap = 6, ensuring that reads mapped across the exon boundary. r exon:exon was calculated by running featureCounts with the juncCounts = TRUE parameter. Plots were generated using ggplot2. For transcript quantification, we constructed a gtf file containing three versions of GENCODE v19 transcript ENST00000260600.5, the longest transcript for ADCY3. The corresponding genomic sequences were extracted using the Cufflinks gffread tool 39 , and a Salmon index was built using Salmon v0.8.2 40 . Untrimmed fastq files were used to quantify the resulting transcripts using Salmon v0.8.2 40 . Calculations of isoform fractions and prediction of functional consequences were done with the R package IsoformSwitchAnalyzeR 12 using standard parameters except the filtering, where geneExpressionCutoff = 1, isoformExpressionCutoff = 0.5 and keepIsoformInAllConditions = TRUE, supplied to the preFilter() function. Hmmer scan v.3.1 41 was used to predict pfamA protein domains as described in the IsoformSwitchAnalyzeR vignette and integrated into the analysis by the analyzePFAM() function. The functional consequences of isoform switches were predicted by IsoformSwitchAnalyzeR's analyzeSwitchConsequences() function. 
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Data exclusions
Describe any data exclusions.
In the association analyses of the Greenlandic cohorts, we excluded individuals for whom we did not have quality filtered Metabochip data, because such data was needed to be able to correct for admixture and relatedness.
Replication
Describe whether the experimental findings were reliably reproduced. The variant was found through exome sequencing and validated by genotyping and with RNA sequencing. Since the identified variant is extremely rare, if at all present, in other populations we were not able to perform replication of the association signal for this exact variant in other populations. Instead, we performed a burden test for other loss-offunction variants in the same gene in other populations. This test supported our initial finding and conclusion.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
NA
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
NA Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study. As described in the online methods, we used the publicly available software package GEMMA to perform all the association tests in the Greenlandic cohorts. To perform the burden test, we used the standard implementation of logistic regression in the statistical software R. Software used for RNA seq analysis included: Trimmomatic, FastQC, Salmon v0.8.2 and R.
For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon request. The Nature Methods guidance for providing algorithms and software for publication may be useful for any submission.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No restrictions
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). 
